Ju-Li Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ju-Li Lin has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Ming Huang
Fujian Medical University Union Hospital
18 shared publications - Long-Long Cao
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
18 shared publications - Chao-Hui Zheng
Fujian Medical University Union Hospital
17 shared publications - Ping Li
Fujian Medical University Union Hospital
17 shared publications - Cheng Yan
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
14 shared publications - Chuan Feng
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
14 shared publications
Latest Publications
- 23 October 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (1) , 455-461
Operational key points of super-low placement of an intestinal decompression tube and its clinical efficacy in elderly patients with incomplete small bowel obstruction
Objective To summarize the key operational points for super-low placement of intestinal decompression tubes and compare the short-term outcomes between super-low placement and traditional placement in elderly patients with incomplete small bowel obstruction. Methods Seventy-eight elderly patients (aged ≥ 60 years) with incomplete small bowel obstruction following abdominal surgery admitted to Fujian Medical University Union Hospital between January 2014 and December 2024 were retrospectively enrolled. The super-low group comprised 55 patients treated with the super-low placement of an intestinal decompression tube. The traditional group comprised 23 patients treated with the traditional placement of intestinal decompression tubes. Short-term outcomes were compared between the two groups. Results The key operational points for super-low placement of the intestinal decompression tube involve three steps: (1) simultaneous insertion of the catheter and guidewire through the cardia; (2) advancement of the guidewire as deeply as possible; and (3) advancement of the catheter over the guidewire. No significant differences were observed in the baseline clinical characteristics between the two groups. The conservative treatment success rate was significantly greater in the super-low group than in the traditional group (89.1% vs. 69.6%, P = 0.035). The postplacement hospital stay was significantly shorter in the super-low group (7.8 ± 4.0 days vs. 16.1 ± 10.6 days, P < 0.001). Compared with the traditional group, the super-low group also demonstrated significantly shorter times to abdominal symptom relief (2.7 ± 2.3 days vs. 5.4 ± 5.0 days, P < 0.001) and time to resumption of flatus/defecation (4.6 ± 3.3 days vs. 8.1 ± 5.3 days, P = 0.005). Conclusion Three key operational points for the super-low placement of intestinal decompression tubes were identified to facilitate learning and dissemination. Super-low placement improved the success rate of conservative treatment and reduced the length of hospital stay in elderly patients with incomplete small bowel obstruction.
- 23 October 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (1) , 455-461
Operational key points of super-low placement of an intestinal decompression tube and its clinical efficacy in elderly patients with incomplete small bowel obstruction
Objective To summarize the key operational points for super-low placement of intestinal decompression tubes and compare the short-term outcomes between super-low placement and traditional placement in elderly patients with incomplete small bowel obstruction. Methods Seventy-eight elderly patients (aged ≥ 60 years) with incomplete small bowel obstruction following abdominal surgery admitted to Fujian Medical University Union Hospital between January 2014 and December 2024 were retrospectively enrolled. The super-low group comprised 55 patients treated with the super-low placement of an intestinal decompression tube. The traditional group comprised 23 patients treated with the traditional placement of intestinal decompression tubes. Short-term outcomes were compared between the two groups. Results The key operational points for super-low placement of the intestinal decompression tube involve three steps: (1) simultaneous insertion of the catheter and guidewire through the cardia; (2) advancement of the guidewire as deeply as possible; and (3) advancement of the catheter over the guidewire. No significant differences were observed in the baseline clinical characteristics between the two groups. The conservative treatment success rate was significantly greater in the super-low group than in the traditional group (89.1% vs. 69.6%, P = 0.035). The postplacement hospital stay was significantly shorter in the super-low group (7.8 ± 4.0 days vs. 16.1 ± 10.6 days, P < 0.001). Compared with the traditional group, the super-low group also demonstrated significantly shorter times to abdominal symptom relief (2.7 ± 2.3 days vs. 5.4 ± 5.0 days, P < 0.001) and time to resumption of flatus/defecation (4.6 ± 3.3 days vs. 8.1 ± 5.3 days, P = 0.005). Conclusion Three key operational points for the super-low placement of intestinal decompression tubes were identified to facilitate learning and dissemination. Super-low placement improved the success rate of conservative treatment and reduced the length of hospital stay in elderly patients with incomplete small bowel obstruction.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
The therapeutic resistances of MDA tumors were abrogated by β-catenin signaling blockade.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
The therapeutic resistances of MDA tumors were abrogated by β-catenin signaling blockade.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
A single-cell transcriptome atlas dissecting heterogeneity of APTc and MDA tumor.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
A single-cell transcriptome atlas dissecting heterogeneity of APTc and MDA tumor.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Immune checkpoint blockade (ICB) therapies have achieved significant breakthroughs in cancer treatment over the past decade. However, ICB is largely ineffective in desert-type gastric cancer due to intrinsic tumor heterogeneity and a highly immunosuppressive tumor microenvironment (TME). Transforming tumors from an immunosuppressive state to an immunostimulatory state is a potential approach to enhance ICB response. In this study, we developed a chromosomal instability–subtype gastric cancer mouse model with an immunoactive TME and a stem cell–originated mouse-derived allograft model with an immunosuppressed TME to investigate mechanisms regulating the tumor immunophenotype and uncover therapeutic strategies to remodel the TME. Blocking β-catenin signaling attenuated the immunochemotherapeutic resistance of mouse-derived allograft tumors. The tyrosine kinase inhibitor apatinib reprogrammed the TME by increasing CD8+ T-cell and IGHA+ plasma cell infiltration and decreasing M2 macrophages, but apatinib also induced PD-L1 and CD80 expression in both human and mouse desert–type tumors. Oxaliplatin decreased the apatinib-induced expression of immune checkpoints and enhanced the antitumor efficacy of immunotherapy. A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type gastric cancer. Collectively, these findings identify potential drug targets for immune desert–type gastric cancer driven by β-catenin signaling.Significance: Apatinib combined with oxaliplatin reprograms the tumor immune microenvironment in desert-type gastric cancer, enhancing the efficacy of immune checkpoint blockade and paving the way for optimized combination immunotherapeutic strategies.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Immune checkpoint blockade (ICB) therapies have achieved significant breakthroughs in cancer treatment over the past decade. However, ICB is largely ineffective in desert-type gastric cancer due to intrinsic tumor heterogeneity and a highly immunosuppressive tumor microenvironment (TME). Transforming tumors from an immunosuppressive state to an immunostimulatory state is a potential approach to enhance ICB response. In this study, we developed a chromosomal instability–subtype gastric cancer mouse model with an immunoactive TME and a stem cell–originated mouse-derived allograft model with an immunosuppressed TME to investigate mechanisms regulating the tumor immunophenotype and uncover therapeutic strategies to remodel the TME. Blocking β-catenin signaling attenuated the immunochemotherapeutic resistance of mouse-derived allograft tumors. The tyrosine kinase inhibitor apatinib reprogrammed the TME by increasing CD8+ T-cell and IGHA+ plasma cell infiltration and decreasing M2 macrophages, but apatinib also induced PD-L1 and CD80 expression in both human and mouse desert–type tumors. Oxaliplatin decreased the apatinib-induced expression of immune checkpoints and enhanced the antitumor efficacy of immunotherapy. A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type gastric cancer. Collectively, these findings identify potential drug targets for immune desert–type gastric cancer driven by β-catenin signaling.Significance: Apatinib combined with oxaliplatin reprograms the tumor immune microenvironment in desert-type gastric cancer, enhancing the efficacy of immune checkpoint blockade and paving the way for optimized combination immunotherapeutic strategies.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 12 patients received neoadjuvant therapy
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 12 patients received neoadjuvant therapy
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 66 patients with gastric cancer in tissue microarray cohort
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 66 patients with gastric cancer in tissue microarray cohort
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Apatinib promotes CD8+ T lymphocyte infiltration and reshapes tumor microenvironment in desert-type GC.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Apatinib promotes CD8+ T lymphocyte infiltration and reshapes tumor microenvironment in desert-type GC.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Neoadjuvant regimen of apatinib plus camrelizumab and chemotherapy is effective for patients with desert-type GC.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Neoadjuvant regimen of apatinib plus camrelizumab and chemotherapy is effective for patients with desert-type GC.